Introduction {#Sec1}
============

Transcription factors (TFs) are crucial determinants of hematopoietic malignancies \[[@CR1], [@CR2]\]. One example of lymphoid neoplasms with distinct dysregulated TF activities is anaplastic large cell lymphoma (ALCL) \[[@CR3], [@CR4]\]. The WHO classification distinguishes ALK-positive (ALK^+^) ALCL, which is characterized by the *NPM--ALK* fusion, and ALK-negative (ALK^--^) ALCL lacking *ALK* translocations \[[@CR5]\]. Both belong to peripheral T-cell lymphomas (PTCLs). Whereas ALK is considered as causative of ALK^+^ ALCL \[[@CR6]\], the pathogenesis of ALK^--^ ALCL is less clarified \[[@CR7], [@CR8]\].

Albeit both ALCL entities show differences in genomic alterations or gene and microRNA expression \[[@CR9]--[@CR11]\], phenotypically they are highly similar and share biological and molecular key aspects \[[@CR12]--[@CR14]\]. In particular, their deregulated TF programs overlap. They share STAT3 and NOTCH1 activation and high-level interferon regulatory factor 4 (IRF4) and MYC (v-myc myelocytomatosis viral oncogene homolog, c-MYC) expression and activity \[[@CR7], [@CR13], [@CR15]--[@CR17]\]. Moreover, we revealed a unique AP-1 activation in ALCL \[[@CR14], [@CR18], [@CR19]\]. Several lines of evidence point toward a crucial role of AP-1 in ALCL: NPM-ALK induces JUNB and JUN \[[@CR20]--[@CR22]\], genomic gains of *JUNB* and *FRA2* loci are found in ALCL \[[@CR23], [@CR14]\], inhibition of AP-1 in ALK^+^ ALCL results in growth arrest and cell death \[[@CR18], [@CR21], [@CR24]\], and JUNB and JUN deletion in mouse models impairs NPM-ALK-driven lymphomagenesis \[[@CR25]\]. Finally, expression of the AP-1 interacting TF BATF3 distinguishes ALCL from other PTCL \[[@CR26]\] and is involved in growth control and survival of ALCL \[[@CR27]\].

BATFs, comprising BATF, BATF2 and BATF3, are basic leucine zipper TFs, which modulate transcription primarily by interaction with JUN proteins \[[@CR28]\]. The lack of a transactivation domain \[[@CR28]\], their redundancy \[[@CR29]\], and the number of interaction partners make functional characterization of BATFs challenging. Initially thought to inhibit transcription, recent work highlighted positive regulatory functions of BATFs \[[@CR28]--[@CR30]\]. IRF4 and BATF enhance each other\'s DNA binding \[[@CR31]\], and they cooperatively bind to so-called AP-1-IRF composite elements (AICEs) \[[@CR29], [@CR31], [@CR32]\]. Moreover, STAT3, IRF4, JUNB and BATF TFs initiate the fate of T helper 17 (TH17) cells, which subsequently enforces expression of the key TH17 TF RORC2 (murine RORγt) \[[@CR33], [@CR34]\]. Regarding this TF network and TH17-associated genes, characteristic features are shared with group 3 innate lymphoid cells (ILC3) \[[@CR35]\].

Given the role of BATF TFs in this regulatory network and expression of STAT3, IRF4, JUNB and BATF3 in ALCL, we investigated expression and function of BATFs in ALCL.

Materials and methods {#Sec2}
=====================

Cell lines, culture conditions and transfections {#Sec3}
------------------------------------------------

ALCL (Karpas-299 \[named K299\], SU-DHL-1, DEL, JB6, SUP-M2, all ALK^+^; Mac-1, Mac-2A, FE-PD, DL40, all ALK^--^), T-cell leukemia-derived (Jurkat, KE-37, Molt-14, H9) and HEK293 cell lines were cultured as described \[[@CR14]\]. Where indicated, 1 μg/ml doxycycline (Dox; Sigma), the ALK inhibitor crizotinib (Selleckchem), the RORC antagonists SR2211, SR1903 (both in-house generated, laboratory PRG) and GSK805 (Calbiochem), or dimethylsulfoxide (DMSO) control was added. For transient transfections and generation of A-Fos-inducible cells, see [Supplementary Methods](#MOESM9){ref-type="media"}.

DNA constructs {#Sec4}
--------------

CMV500-based A-Fos for constitutive expression has been described \[[@CR36]\]. For *BATF*, *BATF3*, *RORC1*, *RORC2*, and pRTS-1-based \[[@CR37]\] inducible A-Fos expression constructs and lentiviral sgRNA and BATF and BATF3 constructs, refer to [Supplementary Methods](#MOESM9){ref-type="media"}.

siRNA-mediated knock-down and CRISPR/Cas9-mediated deletion of BATF and BATF3 in ALCL cell lines, chromatin immunoprecipitation (ChIP) {#Sec5}
--------------------------------------------------------------------------------------------------------------------------------------

Accell small interfering RNAs (siRNAs) were from Dharmacon (Supplementary Table [1](#MOESM1){ref-type="media"}) and passively transfected once into K299 and Mac-1 cells using RPMI-1640 and 1% fetal calf serum. Cells were cultivated at 500--750 nM for each siRNA for 72 h (3 days). Knock-down efficiency was controlled by western blot (WB) at day 3. Functional assays were performed in standard medium. For CRISPR/Cas9-mediated deletion of BATF and BATF3, see [Supplementary Methods](#MOESM9){ref-type="media"} and Supplementary Table [1](#MOESM1){ref-type="media"}; for ChIP, see [Supplementary Methods](#MOESM9){ref-type="media"} and Supplementary Table [2](#MOESM2){ref-type="media"}.

Processing and analysis of microarray data; gene set enrichment analysis (GSEA) and principal component (PC) analysis {#Sec6}
---------------------------------------------------------------------------------------------------------------------

For generation of TH17 and ILC3 signatures, microarray data for TH17, ILC3 and TH1 cells were obtained from GEO (GSE78897) \[[@CR35]\]. Primary ALCL and PTCL data were obtained from GEO (GSE65823, GSE6338 and GSE19069) \[[@CR38]--[@CR40]\]. For microarray analyses of cell lines, supplementation by ILC3 microarray data, GSEA and PC analyses, refer to [Supplementary Methods](#MOESM9){ref-type="media"}.

Additional materials and methods {#Sec7}
--------------------------------

Detailed methodology is described in the [Supplementary Materials and Methods](#MOESM9){ref-type="media"}.

Results {#Sec8}
=======

Characterization of BATF DNA binding and physical interactions of BATFs with JUNB in ALCL {#Sec9}
-----------------------------------------------------------------------------------------

To identify BATF-containing TF complexes in ALCL, we first analyzed AP-1 DNA binding at the classical AP-1 5ʹ-TGA\[G/C\]TCA-3ʹ motif (Supplementary Figure [1A](#MOESM4){ref-type="media"}, top) in a panel of ALK^+^ and ALK^--^ ALCL and T-cell-derived control (*non-ALCL*) cell lines already used in our previous studies \[[@CR13], [@CR18]\]. We verified ALCL-restricted AP-1 DNA binding activity and high-level JUNB and IRF4 expression (Supplementary Figure [1A](#MOESM4){ref-type="media"}) \[[@CR13], [@CR18]\]. Supershift analyses revealed DNA binding of the AP-1/FOS members JUNB and FRA2 \[[@CR14], [@CR18]\], and in addition strong BATF binding (Fig. [1a](#Fig1){ref-type="fig"}, left). In other cellular systems, BATF-JUN drives gene expression together with IRFs from AP-1 IRF composite elements (AICEs) \[[@CR29], [@CR31], [@CR32]\]. DNA binding at AICEs was strong in ALCL, in contrast to non-ALCL (Fig. [1a](#Fig1){ref-type="fig"}, right). Supershifts demonstrated binding of FRA2 (weaker compared with the classical AP-1 motif), JUNB and, more prominently, BATF, as well as BATF3 and IRF4 (Fig. [1b](#Fig1){ref-type="fig"}, left). Immunoprecipitation demonstrated protein--protein interactions between BATF and BATF3 with JUNB specifically in ALCL cell lines (Fig. [1b](#Fig1){ref-type="fig"}, right, and Supplementary Figure [1B](#MOESM4){ref-type="media"}).Fig. 1BATF and BATF3 DNA binding, co-immunoprecipitation and expression in ALCL. **a** Left, EMSA of AP-1 TPA responsive element (TRE) complexes without (-) or with addition of specific antibodies, or isotype control (IC). Positions of AP-1 complexes, supershifts (ss) and a nonspecific band (n.s.) are indicated. Right, EMSA of IRF/AP-1 DNA binding at AICEs (AICE_Bcl11b; AICE; AICE_IL12RB). Underlined, IRF motif; bold, AP-1 motif; gray, intervening bases. The free probe of one representative EMSA is shown. **b** Left, EMSA of AICE_Bcl11b, performed as in **a**. Right, JUNB and BATF co-immunoprecipitations with anti-JUNB (top), anti-BATF (bottom) or isotype controls (IC). (Co-)immunoprecipitated proteins were detected by immunoblotting (WB). β-Actin and input were controls. **c** Left, BATF and BATF3 were analyzed at mRNA levels by RT-PCR (top) and at protein level by immunoblotting of nuclear extracts (bottom). *GAPDH* and PARP1 were controls. Right, BATF and BATF3 IHC of primary lymphomas. Top, BATF IHC of an ALK^+^ ALCL **a**, an ALK^--^ ALCL**b** and a mantle cell lymphoma \[MCL; **c**\]. Bottom, BATF3 IHC of an ALK^+^ ALCL **d**, an ALK^--^ ALCL **e** and a DLBCL **f**

High-level expression of BATF and BATF3 in ALCL {#Sec10}
-----------------------------------------------

The distinct DNA binding of BATF and BATF3 in ALCL indicated cell-type-specific expression. Indeed, *BATF* mRNA was largely restricted to, and *BATF3* was exclusively expressed in ALCL cell lines (Fig. [1c](#Fig1){ref-type="fig"}, upper left). *BATF2* was not expressed (data not shown). We confirmed high BATF and BATF3 protein expression in all ALCL cell lines (Fig. [1c](#Fig1){ref-type="fig"}, lower left, and Supplementary Figure [1](#MOESM4){ref-type="media"}C and [1D](#MOESM4){ref-type="media"}). The highest BATF levels in some ALK^--^ cell lines corresponded to their somewhat stronger DNA binding at AICE_IL12RB (see Fig. [1a](#Fig1){ref-type="fig"}).

Immunohistochemistry of BATF and BATF3 in human lymphoma specimens demonstrated nuclear localization (Fig. [1c](#Fig1){ref-type="fig"}, right). Among 69 non-ALCL B-NHL and T-NHL, none of the mantle cell (MCL; 0/7), follicular (FL; 0/11) and Burkitt lymphomas (BL; 0/11) expressed BATF. expressed BATF, and 15 of 20 DLBCL showed varying numbers of positive lymphoma cells, whereas all CLL cases (9/9; only in proliferative centers), 2/2 NLPHL and 9/9 PTCL (NOS) were BATF positive. We concluded that BATF expression is associated with distinct lymphoma subtypes and cellular subpopulations. Importantly, strong staining was observed in 16/16 ALCL (7 ALK^+^/9 ALK^--^) (Fig. [1c](#Fig1){ref-type="fig"} right, top) and 8/8 classical Hodgkin lymphoma (cHL) cases.

BATF3 showed a more restricted expression pattern. In total, 16/16 ALCL (7 ALK^+^/9 ALK^--^) (Fig. [1c](#Fig1){ref-type="fig"} right, bottom) and 8/8 cHL strongly stained positive, whereas among 69 B-NHL and T-NHL (20 DLBCL, 10 MCL, 9 CLL, 11 FL, 8 BL, 9 PTCL, 2 NLPHL) only 1 CLL sample was BATF3 positive. Thus, simultaneous BATF and BATF3 expression was unique to ALCL and cHL.

CRISPR/Cas9-mediated deletion and siRNA knock-down of BATF and/or BATF3 in ALCL {#Sec11}
-------------------------------------------------------------------------------

We next defined the role of BATF and BATF3 in ALCL by gene-specific inactivation by CRISPR/Cas9-mediated knock-out (KO) in K299, SUP-M2 and Mac-1 cells (Figs. [2a, b](#Fig2){ref-type="fig"}). Interestingly, following BATF3 deletion, BATF was upregulated. This was also observed in SUP-M2 cells, in which BATF was virtually absent at baseline (Supplementary Figure [1D](#MOESM4){ref-type="media"}). Deletion of BATF or BATF3 in K299 (Fig. [2a](#Fig2){ref-type="fig"}, left) or BATF3 in SUP-M2 cells (Fig. [2a](#Fig2){ref-type="fig"}, center) resulted in sustained growth retardation, but did not alter the growth of Mac-1, in which we, however, observed the strongest counterregulation of BATF and BATF3 (Fig. [2a](#Fig2){ref-type="fig"}, right).Fig. 2CRISPR/Cas9-mediated deletion and siRNA-mediated knock-down of BATF and BATF3 in ALCL. **a** CRISPR/Cas9-mediated deletion of BATF and/or BATF3 in K299 (left), SUP-M2 (center) and Mac-1 (right) cells. Top, immunoblotting of wild-type (WT), control-treated (CRISPR CTL), BATF KO and/or BATF3 KO cells for BATF and BATF3. Note the compensatory increase of BATF following BATF3 deletion. Bottom, cell numbers are shown over time. **b** Left and center, BATF3 single knock-out Mac-1 (left) and K299 (center) cells were transduced with GFP-labeled vector encoding BATF gRNA (BATF KO) or non-targeting control (CRISPR CTL). The percentage of GFP-positive cells over time is indicated. Right, xenotransplantation of K299 WT, BATF KO and BATF3 KO cells on NSG mice. Tumor weight at day 14 is shown in gram (g). Far right, representative tumors at day 14. **c** siRNA-mediated knock-down of BATF and/or BATF3 in Mac-1. Cells were treated with control siRNAs (siCTL \#1 and siCTL \#2), siRNAs targeting BATF (siBATF \#2, siBATF \#3 and siBATF \#4; left) or BATF3 (siBATF3 \#1 and siBATF3 \#2; center), or respective combinations (right). Cell numbers (top), \[^3^H\]-thymidine incorporation (center) and percentage of Annexin V-positive cells (bottom) are shown over time. \*\**P* \< 0.01; \*\*\**P* \< 0.001; n.s., not significant

We were unable to generate BATF and BATF3 double KO ALCL cells, suggesting lethality of double BATF KO to ALCL. To test this, we monitored the fate of CRISPR/Cas9-mediated BATF and BATF3 double KO cells by transducing BATF3 single KO cells with BATF-targeting guide-RNA (gRNA) (Fig. [2b](#Fig2){ref-type="fig"}, left and center, Supplementary Figure [2A](#MOESM5){ref-type="media"}). In Mac-1 cells, despite no effect of BATF single KO (see Fig. [2a](#Fig2){ref-type="fig"}), trans duction of BATF3 single KO cells with BATF-directed gRNA led to a rapid loss of green fluorescent protein (GFP)-positive cells. A similar, somewhat less pronounced effect was observed in K299 cells, which, however, already showed growth retardation in BATF3 single KO cells (see Fig. [2a](#Fig2){ref-type="fig"}). Finally, xenotransplantation of K299 BATF KO cells produced significantly smaller tumors compared with WT cells (Fig. [2b](#Fig2){ref-type="fig"}, right), with a similar tendency for BATF3 KO tumors.

In a complementary approach, we performed siRNA-mediated knock-down of both *BATF*s (Fig. [2c](#Fig2){ref-type="fig"} and Supplementary Figures [2B](#MOESM5){ref-type="media"} and [2C](#MOESM5){ref-type="media"}). Single knock-down of BATF did not alter viability of Mac-1 cells (Fig. [2c](#Fig2){ref-type="fig"}, left), whereas BATF3 knock-down moderately inhibited growth and induced cell death (Fig. [2c](#Fig2){ref-type="fig"}, center). Importantly, simultaneous knock-down of both BATFs resulted in strong growth inhibition and apoptotic death (Fig. [2c](#Fig2){ref-type="fig"}, right), which reflected our inability to generate double BATF and BATF3 KO clones using CRISPR techniques. Similar results were obtained with K299 cells (Supplementary Figure [2C](#MOESM5){ref-type="media"}). As specificity control, reversion of cellular toxicity was shown by concomitant ectopic BATF and BATF3 expression (Supplementary Figure [3A](#MOESM6){ref-type="media"}).

Induction of cell death following global abrogation of AP-1 DNA binding activity in ALCL {#Sec12}
----------------------------------------------------------------------------------------

In an independent approach, we globally inhibited AP-1 by a dominant repressor of AP-1 and leucine zipper TFs, such as BATFs, named A-Fos \[[@CR36]\]. This complemented our approaches targeting BATFs, as BATFs have low DNA affinity and require JUN proteins, mainly JUNB, for heterodimer formation and DNA binding \[[@CR28]\]. We generated Dox-inducible A-Fos FE-PD cells (Fig. [3](#Fig3){ref-type="fig"} and Supplementary Figure [3B](#MOESM6){ref-type="media"}), in which AP-1 activity was virtually abolished following Dox addition (Fig. [3](#Fig3){ref-type="fig"}, left). This inhibited cell growth (Supplementary Figure [3B](#MOESM6){ref-type="media"}) and induced cell death (Fig. [3](#Fig3){ref-type="fig"}, right). Similar results were obtained following transient A-Fos expression in K299 (Supplementary Figure [3C](#MOESM6){ref-type="media"}). Thus, constitutive AP-1/BATF activity is essential for viability of ALK^+^ and ALK^--^ ALCL cells.Fig. 3Inhibition of global AP-1 activity by its dominant-negative A-Fos in FE-PD cells. Inducible A-Fos expression abrogates constitutive AP-1. Left, analysis of enriched GFP-positive cells by WB for A-Fos expression (top; FLAG antibody) and EMSA for DNA binding to TRE site (center, top) and BCL_11b AICE (center, bottom) after Dox addition for the indicated times. β-Actin and Sp1 DNA binding were controls. Two independent experiments (\#1 and \#2) are shown. Right, percentage of viable cells following Dox induction measured by PI staining and flow cytometry over time. \*\*\**P* \< 0.001

ALCL shows a gene expression pattern characteristic for TH17 and ILC3 cells {#Sec13}
---------------------------------------------------------------------------

JUN-BATF, IRF4 and STAT3 coordinate TH17 gene expression \[[@CR33]\]. As all these TFs are active in ALCL, we hypothesized that their combined activity imposes a TH17 cellular fate in ALCL. Indeed, ALCL cell lines consistently expressed TH17-associated genes (Fig. [4a](#Fig4){ref-type="fig"}), including *AHR*, *IL1R1*, *IL4R*, *IL18R1*, *IL22, IL23R* and *IL26*. Given the absence of T-cell receptor (TCR) rearrangement in a (minor) subset of ALCL cases \[[@CR41], [@CR42]\], we reasoned that ALCL cells could be derived alternatively from ILC3 cells. These cells are characterized by the absence of BCR or TCR gene rearrangements and have, compared with TH17 cells, an overlapping but distinct gene expression pattern \[[@CR35]\].Fig. 4TH17/ILC3 gene expression in ALCL and link to the deregulated BATF/BATF3/AP-1 activity. **a** mRNA expression of TH17/ILC3-associated genes and, as control, *GAPDH* were analyzed by RT-PCR. **b** More global approaches to TH17/ILC3 gene expression in ALCL. Upper panels, GSEA of differentially expressed genes between ALCL (K299, SU-DHL-1, DEL, JB6, FE-PD, Mac-2A) and T control (T) cell lines (Jurkat, KE-37, Molt-14, H9) based on TH17 (left) and ILC3 (right) top 100 upregulated genes. Lower panels, PC analyses of ALK^+^ and ALK^--^ ALCL and T control samples based on 100 top differentially expressed TH17 (left) or ILC3 (right) genes, separating ALCL and T-cell lines along the PC1 axis. PCAs were supplemented by projection of ILC3 samples \[[@CR45]\]. n.s., not significant; \**P* ≤ 0.05; \*\**P* ≤ 0.01; \*\*\**P* ≤ 0.001; \*\*\*\**P* ≤ 0.0001. **c** BATF3 ChIP from K299 cells. Input and precipitated DNA were amplified by qPCR for the indicated promoter or enhancer regions. Combined data of two biological replicates are shown as mean ±  SEM. **d** Inhibition of AP-1 downregulates TH17/ILC3 genes. Enriched A-Fos or Mock transfected K299 cells were analyzed by RT-PCR for TH17/ILC3 genes. Two (\#1 and \#2) of four independent experiments are shown. **e** Analysis of TH17/ILC3 genes in K299 cells with double BATF and BATF3 KO at day 13 following lentiviral transduction. qPCR-based expression of the indicated genes in control cells (CRISPR CTL) or cells transduced with a combination of sgRNAs targeting BATF and BATF3 (BATF + BATF3 DKO). BATF and BATF3 were analyzed to verify their KO. The expression level in CRISPR CTL cells was set 1. Error bars denote 95% CIs. One out of three independent experiments is shown. \**P* ≤ 0.05; \*\**P* ≤ 0.01; \*\*\**P* ≤ 0.001; n.s., not significant

To test whether a TH17- or ILC3-like signature was an inherent feature of the overall ALCL expression pattern, we performed GSEAs (Fig. [4b](#Fig4){ref-type="fig"}, top). Based on published gene expression data \[[@CR35]\], we defined TH17 and ILC3 signatures, using the top 100 up- or downregulated genes compared with TH1 cells. Our ALCL cell lines significantly enriched genes upregulated in TH17 cells (Fig. [4b](#Fig4){ref-type="fig"}, top, left) and even more prominently ILC3-upregulated genes (Fig. [4b](#Fig4){ref-type="fig"}, top, right). ILC3 signature leading edge genes are shown in Supplementary Table [3](#MOESM3){ref-type="media"}. Consistently, principal component analysis (PCA) of ALK^+^ (K299, SU-DHL-1, DEL, JB6), ALK^--^ (FE-PD, Mac-2A) and control (T; Jurkat, KE-37, Molt-14, H9) samples based on the top 100 differentially expressed genes between TH17 and ILC3 and TH1 signatures revealed a clear separation of ALCL and control cells along PC1 (Fig. [4b](#Fig4){ref-type="fig"}, bottom). Moreover, ALCL cells were localized closer to projected ILC3, again more significant for ILC3 signatures (*P*-values ≤ 1.6E--9 for TH17 signature based PCA and 9.5E--17 for ILC3). This suggested an in-between localization of ALCL between the ILC3 and TH17 phenotypes with a stronger skewing towards an ILC3 profile.

Expression of TH17/ILC3 genes in primary ALCL; IL-22, IL-17A and IL-17F are secreted by ALCL cell lines, IL-17A and IL-17F detectable in ALCL patients {#Sec14}
------------------------------------------------------------------------------------------------------------------------------------------------------

We next aimed to confirm expression of TH17- and ILC3-associated genes in primary lymphomas. In the majority of primary ALCL samples, TH17--/ILC3 genes were much stronger or even exclusively expressed compared with NHL controls (Supplementary Figure [4A](#MOESM7){ref-type="media"}). Moreover, IL-22 was secreted by three ALK^--^ cell lines and IL-17A and IL-17F by several ALCL cell lines (Supplementary Figure [4B](#MOESM7){ref-type="media"}). IL-17A was detectable in three of 21 pretreatment serum/plasma samples of ALK^+^ ALCL patients and one healthy control, whereas it was undetectable in patients in remission (Supplementary Figure [4C](#MOESM7){ref-type="media"}) (*P* = 0.48). IL-17F levels were high in 4 of 21 ALCL patients, whereas no healthy control or patient in remission exhibited measurable IL-17F (Supplementary Figure [4C](#MOESM7){ref-type="media"}). Although there was only a tendency toward a higher mean IL-17F level in ALK^+^ ALCL patients (*P *= 0.08), these data suggest specific IL-17F upregulation in distinct ALK^+^ ALCL patients. We did not observe a significant correlation with other clinical or biological parameters (data not shown).

Recruitment of BATFs and JUNB to regulatory regions of TH17/ILC3 genes and dependency of TH17/ILC3 genes on AP-1/BATFs in ALCL {#Sec15}
------------------------------------------------------------------------------------------------------------------------------

A direct regulation of TH17-/ILC3-associated genes by AP-1/BATF was investigated by ChIPs of BATF, BATF3 and JUNB. We analyzed promoter or enhancer regions of *IL1R1*, *IL4R*, *IL12RB*, *IL17A*, *IL18R1, IL22*, *IL23R* and *IL26* in three ALCL cell lines and Jurkat controls (Fig. [4c](#Fig4){ref-type="fig"} and Supplementary Figure [5A](#MOESM8){ref-type="media"} and [5B](#MOESM8){ref-type="media"}). Most of the regulatory regions showed strong BATF, BATF3 and JUNB recruitment in ALCL cells, which was not observed in Jurkat. Functionally, we confirmed AP-1 involvement in the upregulation of TH17/ILC3 genes, as expression of *AHR*, *CCL20*, *IL4R*, *IL17A*, *IL22*, *IL23R* and *IL26* decreased following AP-1 inhibition (Fig. [4d](#Fig4){ref-type="fig"}). Furthermore, K299 showed decreased expression of *AHR*, *IL1R1*, *IL6R*, *IL26* and *RORC2* after enrichment of cells with simultaneous gRNA-mediated double KO of BATF and BATF3 at day 13 after transduction (Fig. [4e](#Fig4){ref-type="fig"}).

Primary ALCL shows a gene expression pattern characteristic for ILC3, while taking an intermediate position between two groups of PTCL with respect to TH17 signature genes {#Sec16}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To globally approach the concept of TH17/ILC3 skewing of primary ALCL, we performed GSEA with microarray data of primary ALCL and PTCL samples used in previous studies (Fig. [5](#Fig5){ref-type="fig"}) \[[@CR38]--[@CR40]\]. A correlation analysis of gene expression profiles of all samples (bracket \[a\]) demonstrated one central ALCL cluster flanked by two distinct PTCL clusters, positioned in bracket \[b\] and \[c\] of Fig. [5a](#Fig5){ref-type="fig"}. In an overall analysis including all samples (Fig. [5a](#Fig5){ref-type="fig"}, bracket \[a\]), the ILC3 signature enriched in ALCL (Fig. [5b](#Fig5){ref-type="fig"}, center top panel). In contrast, the TH17 signature demonstrated a trend toward an enrichment in PTCL (Fig. [5b](#Fig5){ref-type="fig"}, center bottom panel). The GSEA between both PTCL clusters revealed a strong TH17 signature enrichment in PTCLs positioned in bracket \[b\] compared with those positioned in bracket \[c\] (NES 3.2556; FDR \< 0.0001; data not shown). The TH17-like PTCL in bracket \[b\] also showed an enrichment of the TH17 signature when compared with ALCL (Fig. [5b](#Fig5){ref-type="fig"}, left bottom). The ALCL, however, showed an enrichment of the TH17 signature when compared with PTCLs positioned in bracket \[c\] (Fig. [5b](#Fig5){ref-type="fig"}, right bottom). The ILC3 signature was enriched in ALCL when compared with any of the PTCL clusters (Fig. [5b](#Fig5){ref-type="fig"}, top). We concluded that gene expression pattern characteristic for ILC3 is a common feature of ALCL, whereas, regarding TH17 signature genes, ALCL takes an intermediate position between PTCL with or without expression of TH17 genes.Fig. 5TH17/ILC3 gene set enrichment analyses of primary ALCL and PTCL. **a** Pearson correlation heatmap between ALCL and PTCL samples. Samples are clustered by the Euclidean distance and separate into three major clusters. **b** GSEA of ALCL and PTCL samples from indicated clusters, marked by brackets underneath the heatmap shown in **a**. Note, although ALCL shows an overall enrichment of the ILC3 signature (GSEA of upper row), the TH17 signature enrichment (GSEA of lower row) is decreasing from left to the right

Expression of RORC2 (RORγt) in ALCL; RORC inhibition results in cell death induction in ALCL and synergizes with ALK inhibitors {#Sec17}
-------------------------------------------------------------------------------------------------------------------------------

TH17 and ILC3 cells are characterized by a unique expression of RORC2, also known as RORγt \[[@CR43]--[@CR45], [@CR46]\]. *RORC2* mRNA was detectable in five of eight ALCL cell lines, but none of the controls (Fig. [6a](#Fig6){ref-type="fig"}, upper left). *RORC1* mRNA was stronger expressed in ALCL cell lines. At the protein level, we confirmed RORC overexpression and RORC2 restriction to ALCL cell lines (Fig. [6a](#Fig6){ref-type="fig"}, lower left, and Supplementary Figure [5C](#MOESM8){ref-type="media"}, left). Furthermore, robust *RORC2* mRNA expression was detectable in most primary ALCL specimens in contrast to NHL, including five PTCL-NOS (Supplementary Figure [5C](#MOESM8){ref-type="media"}, center and right). Functionally, *RORC2* expression decreased following AP-1/BATF inhibition by A-Fos (Fig. [6a](#Fig6){ref-type="fig"}, right).Fig. 6Expression and inhibition of RORC2 in ALCL. **a** Left, analysis of *RORC1* and *RORC2* mRNA by RT-PCR (top) and RORC protein expression by immunoblotting of nuclear extracts (bottom). *GAPDH* and PARP1 are controls. Right, AP-1 inhibition downregulates *RORC2*. K299 cell were treated as in Fig. [4d](#Fig4){ref-type="fig"}, and *RORC2* and *GAPDH* mRNA were analyzed by RT-PCR (top), and RORC2 expression changes at the protein level by WB (bottom). Two (\#1 and \#2) of four independent experiments are shown. **b** RORC inhibition by small compounds induces cell death of ALCL cell lines. Cells were treated with 5 μM of RORC inhibitors SR2211 or SR1903, or the control (DMSO), and the percentage of viable cells was analyzed by PI staining. One of three independent experiments is shown. (**c**) Enforced cell death induction by crizotinib in combination with RORC inhibitors. The ALK^+^ cell lines K299, DEL and JB6 cells were left untreated, or treated with DMSO control, the RORC inhibitors SR2211 (7.5 μΜ), SR1903 (7.5 μΜ) and GSK805 (7.5 μM), or 25 nM crizotinib (Crizo) alone, or the different RORC inhibitors together with crizotinib. Cell death was analyzed by Annexin V-FITC/PI staining. The percentage of viable cells is shown. Experiments were performed in triplicates and results are shown as mean ± SD. One of three independent experiments is shown. \**P* \< 0.05; \*\*\**P* \< 0.001; n.s., not significant

Finally, we investigated the effect of pharmacological RORC inhibition in ALCL. Treatment of ALCL cell lines with the inhibitory RORC modulators SR2211 (ref. [@CR47]) and SR1903 (a close analog of SR2211) resulted in decreased viable cells over time (Fig. [6b](#Fig6){ref-type="fig"}, top), whereas no effect was observed in cells without (KE-37) or low level (Jurkat) RORC expression and in FE-PD cells with RORC1 but no RORC2 expression (Fig. [6b](#Fig6){ref-type="fig"}, bottom). Moreover, we investigated the effect of RORC inhibitors SR2211, SR1903 and GSK805 (ref. [@CR48]) in combination with ALK inhibition in the ALK^+^ ALCL cell lines K299, DEL and JB6 (Fig. [6c](#Fig6){ref-type="fig"}). The combination of crizotinib with RORC inhibitors enhanced cell death induction.

Discussion {#Sec18}
==========

We demonstrate that ALK^+^ and ALK^--^ ALCL are characterized by an unprecedented activation of the AP-1 family and leucine zipper TFs BATF and BATF3, and that simultaneous high-level expression of both BATFs is a particular feature of ALCL. In accordance with the fact that BATF3 distinguishes ALCL from other PTCL \[[@CR26], [@CR27]\], BATF and BATF3 thus add a new layer of complexity to deregulated AP-1 in ALCL \[[@CR14], [@CR18], [@CR19]\]. Remarkably, although NPM-ALK induces JUNB \[[@CR21]\], ALK^+^ and ALK^--^ ALCL neither differ in their global AP-1 activity nor in expression of distinct AP-1 factors \[refs. [@CR14], [@CR18], [@CR19] and this work\], which supports our hypothesis that they share a common pathogenic mechanism \[[@CR49], [@CR50]\]. In favor of this, the epigenome between ALK^+^ and ALK^--^ ALCL is highly similar \[[@CR49]\]. Apart from ALCL, we identified a concomitant expression of BATF and, as only recently demonstrated \[[@CR27]\], BATF3 in cHL, which is in line with the in cHL known constitutive AP-1 activity and shared key TF activities in cHL and ALCL \[[@CR16], [@CR18], [@CR19]\].

AP-1 forms homo- or heterodimers and exerts cell-type and differentiation stage-specific functions \[[@CR51]\]. Furthermore, AP-1 effects certainly differ between transient and the long-term activation observed in ALCL, as known, for example, NF-κB \[[@CR52]\]. We present evidence that BATF and BATF3 are essential components of the TF network in ALCL. First, deletion of BATF or BATF3 caused growth retardation *in vitro* and *in vivo*, in line with a recently published study on BATF3 in ALCL \[[@CR27]\]. Our inability to generate BATF and BATF3 double KO cells indicates lethality of combined BATF deletion. Second, we observed a comparable phenotype with siRNA-mediated BATF knock-down, in which the combined BATF and BATF3 knock-down resulted in pronounced growth arrest and cell death induction. The cross-regulation of BATF and BATF3 detected in our cell lines and in genetically manipulated mice and a functional redundancy \[[@CR28], [@CR29]\] might attenuate effects of targeting single BATFs. BATFs modify transcriptional activity by interaction with AP-1 TFs like JUNB and JUN \[[@CR28]\], both highly activated in ALCL \[[@CR18], [@CR24]\]. In line with their concerted activity, global AP-1 inhibition caused death of ALCL cells (this work and ref. [@CR18]).

Furthermore, we describe a composite DNA binding activity at AICEs with IRF4, which is known from TH17 cells \[[@CR30], [@CR32]--[@CR34]\]. In ALK^+^ ALCL, expression of some TH17 genes has been reported \[[@CR40], [@CR53], [@CR54]\], and NPM-ALK-induced miR-135b enforces IL-17 production \[[@CR54]\]. We demonstrate that TH17 gene expression is a unifying feature of ALK^+^ and ALK^--^ ALCL, and their expression depends at least in part on AP-1/BATFs. By a comprehensive analysis of the TH17 signature in primary ALCL and PTCL, we identified two PTCL groups, one with strong TH17 signature and one without, whereas ALCL were taking an intermediate position between these PTCL groups. Whereas the biological and clinical relevance of TH17 gene expression in PTCL has to be investigated in future studies, these data confirmed partial TH17 skewing of primary ALCL.

Remarkably, the ILC3 gene set, which overlaps with that of TH17 cells \[[@CR35]\], showed a consistent enrichment in ALCL, irrespective of the PTCL comparison. This is of particular relevance regarding the cellular origin of ALCL and opens a new view on ALCL pathogenesis. Approximately 14% of ALCL show germline TCR configuration \[[@CR41]\]. The absence of BCR or TCR rearrangements is as much a hallmark of ILC3 as the lack of typical B or T-cell markers \[[@CR55], [@CR56]\]. ILC3 are enriched in human tonsils and the intestinal lamina propria, and circulate in the peripheral blood \[[@CR55]\]. Whereas nearly all known hematopoietic cell types give rise to malignancies, no ILC3-derived neoplasm is currently known. We propose that a (minor) subfraction of ALCL originates from ILC3. The expression of key ILC3 genes, the lack of B or T lymphoid surface markers, the lack of a genomic lymphoid fingerprint in an ALCL fraction and the frequent expression of IL-22 \[[@CR53], [@CR57]\] are in accordance with such a hypothesis. Alternatively, the deregulated TF network might superimpose a TH17/ILC3 cellular fate on ALCL cells.

Our work provides new aspects for targeted treatment strategies for ALCL. Inhibitors of TH17 cells are developed due to TH17 cell involvement in autoimmune and inflammatory diseases \[[@CR58], [@CR59]--[@CR61]\]. Hence, interference with TH17 gene activity might represent a treatment strategy for ALK^+^ and ALK^--^ ALCL. Among ALK^+^ ALCL patients, treatment with ALK inhibitors exerts long-term disease control \[[@CR62]\], but is obviously unable to eradicate the respective lymphoma clone \[[@CR63]\]. The synergistic activity of RORC inhibitors together with ALK inhibitors might eradicate persisting ALCL cells. In addition, we provide the basis for exploring interference with, for example, IL-17 and IL-26 circuits and further evaluation of TH17-related cytokines as diagnostic and prognostic markers for ALCL, as also suggested by an independent study \[[@CR53]\].

Overall, we have identified BATF and BATF3 as essential components of the gene regulatory network in ALCL and have demonstrated their pathogenic and therapeutic relevance. Furthermore, we suggest that a subset of ALCL originate from ILC3, a finding that has to be elaborated in future studies.
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